Background Private for-profit outlets are important treatment sources for malaria in most endemic countries. However, these outlets constitute only the last link in a chain of businesses that includes manufacturers, importers and wholesalers, all of which influence the availability, price and quality of antimalarials patients can access. We present evidence on the composition, characteristics and operation of these distribution chains and of the businesses that comprise them in six endemic countries (Benin, Cambodia, Democratic Republic of Congo, Nigeria, Uganda and Zambia). Methods and Findings We conducted nationally representative surveys of antimalarial wholesalers during 2009–2010 using an innovative sampling approach that captured registered and unregistered distribution channels, complemented by in-depth interviews with a range of stakeholders. Antimalarial distribution chains were pyramidal in shape, with antimalarials passing through a maximum of 4–6 steps between manufacturer and retailer; however, most likely pass through 2–3 steps. Less efficacious non-artemisinin therapies (e.g. chloroquine) dominated weekly sales volumes among African wholesalers, while volumes for more efficacious artemisinin-based combination therapies (ACTs) were many times smaller. ACT sales predominated only in Cambodia. In all countries, consumer demand was the principal consideration when selecting products to stock. Selling prices and reputation were key considerations regarding supplier choice. Business practices varied across countries, with large differences in the proportions of wholesalers offering credit and delivery services to customers, and the types of distribution models adopted by businesses. Regulatory compliance also varied across countries, particularly with respect to licensing. The proportion of wholesalers possessing any up-to-date licence from national regulators was lowest in Benin and Nigeria, where vendors in traditional markets are important antimalarial supply sources. Conclusions The structure and characteristics of antimalarial distribution chains vary across countries; therefore, understanding the wholesalers that comprise them should inform efforts aiming to improve access to quality treatment through the private sector.
References
[1]
Bennett S, McPake B, Mills A, editors (1997) Private Health Providers in Developing Countries, Serving the Public Interest? London and New York: Zed Publishers.
[2]
Berman P, Laura R (1996) The role of private providers in maternal and child health and family planning services in developing countries. Health Policy Plan 11: 142–155. doi: 10.1093/heapol/11.2.142
[3]
Hanson K, Berman P (1998) Private health care providers in developing countries: a preliminary analysis of levels and composition. Health Policy and Planning 13: 195–211. doi: 10.1093/heapol/13.3.195
[4]
Patouillard E, Hanson KG, Goodman CA (2010) Retail sector distribution chains for malaria treatment in the developing world: a review of the literature. Malar J 9: 50. doi: 10.1186/1475-2875-9-50
[5]
Alba S, Dillip A, Hetzel MW, Mayumana I, Mshana C, et al. (2010) Improvements in access to malaria treatment in Tanzania following community, retail sector and health facility interventions – a user perspective. Malar J 9: 163. doi: 10.1186/1475-2875-9-163
[6]
Awor P, Wamani H, Bwire G, Jagoe G, Peterson S (2012) Private sector drug shops in integrated community case management of malaria, pneumonia, and diarrhea in children in Uganda. Am J Trop Med Hyg 87: 92–96. doi: 10.4269/ajtmh.2012.11-0791
[7]
Chaturvedi HK, Mahanta J, Pandey A (2009) Treatment-seeking for febrile illness in north-east India: an epidemiological study in the malaria endemic zone. Malar J 8: 301. doi: 10.1186/1475-2875-8-301
[8]
Cohen JM, Woolsey AM, Sabot OJ, Gething PW, Tatem AJ, et al. (2012) Public health. Optimizing investments in malaria treatment and diagnosis. Science 338: 612–614. doi: 10.1126/science.1229045
[9]
Kahabuka C, Kvale G, Hinderaker SG (2013) Care-seeking and management of common childhood illnesses in Tanzania–results from the 2010 Demographic and Health Survey. PLoS One 8: e58789. doi: 10.1371/journal.pone.0058789
[10]
Lalchhuanawma R, Murhekar MV (2012) Health-seeking behaviour for febrile illness in malaria-endemic Kolasib district, Mizoram, India. Int Health 4: 314–319 doi:310.1016/j.inhe.2012.1006.1003.
[11]
Nabyonga Orem J, Mugisha F, Okui AP, Musango L, Kirigia JM (2013) Health care seeking patterns and determinants of out-of-pocket expenditure for malaria for the children under-five in Uganda. Malar J 12 175 10.1186/1475–2875-1112-1175. doi: 10.1186/1475-2875-12-175
[12]
Nonaka D, Vongseththa K, Kobayashi J, Bounyadeth S, Kano S, et al. (2009) Public and private sector treatment of malaria in Lao PDR. Acta Trop 112: 283–287 doi:210.1016/j.actatropica.2009.1008.1013. Epub 2009 Aug 1014.
[13]
Noor AM, Rage IA, Moonen B, Snow RW (2009) Health service providers in Somalia: their readiness to provide malaria case-management. Malar J 8 100 10.1186/1475–2875-1188-1100. doi: 10.1186/1475-2875-8-100
[14]
Okeke TA, Okeibunor JC (2010) Rural-urban differences in health-seeking for the treatment of childhood malaria in south-east Nigeria. Health Policy 95: 62–68 doi:10.1016/j.healthpol.2009.1011.1005. Epub 2009 Dec 1018.
[15]
Onwujekwe O, Hanson K, Uzochukwu B, Ezeoke O, Eze S, et al. (2010) Geographic inequities in provision and utilization of malaria treatment services in southeast Nigeria: diagnosis, providers and drugs. Health Policy 94: 144–149 doi:110.1016/j.healthpol.2009.1009.1010.
[16]
Rutebemberwa E, Pariyo G, Peterson S, Tomson G, Kallander K (2009) Utilization of public or private health care providers by febrile children after user fee removal in Uganda. Malar J 8 45.: –10.1186/1475–2875-1188-1145.
[17]
Littrell M, Gatakaa H, Evance I, Poyer S, Njogu J, et al. (2011) Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries. Malar J 10: 327. doi: 10.1186/1475-2875-10-327
[18]
Littrell M, Gatakaa H, Phok S, Allen H, Yeung S, et al. (2011) Case management of malaria fever in Cambodia: results from national anti-malarial outlet and household surveys. Malar J 10: 328. doi: 10.1186/1475-2875-10-328
[19]
O’Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, et al. (2011) Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J 10: 326. doi: 10.1186/1475-2875-10-326
[20]
Yeung S, Patouillard E, Allen H, Socheat D (2011) Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia. Malar J 10: 243. doi: 10.1186/1475-2875-10-243
[21]
Shewchuk T, O’Connell KA, Goodman C, Hanson K, Chapman S, et al. (2011) The ACTwatch project: methods to describe anti-malarial markets in seven countries. Malar J 10: 325. doi: 10.1186/1475-2875-10-325
[22]
Global Malaria Programme (2012) World malaria report 2012. Geneva: World Health Organization.
[23]
Patouillard E (2012) An economic analysis of the market for malaria treatment in Cambodia. London: London School of Hygiene and Tropical Medicine, University of London.
[24]
StataCorp (2009) Stata Statistical Software: Release 11. College Station, TX: StataCorp LP.
[25]
StataCorp (2011) Stata Statistical Software: Release 12. College Station, TX: StataCorp LP.
[26]
Tougher S, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, et al. (2012) Effect of the Affordable Medicines Facility–malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. Lancet 380: 1916–1926. doi: 10.1016/s0140-6736(12)61732-2
[27]
O’Cathain A, Thomas K (2006) Chapter 9 Combining qualitative and quantitative methods. In: Pope C, Mays N, editors. Qualitative research in health care, 3rd ed. Oxford: Blackwell Publishing Ltd.
[28]
Pope C, Ziebland S, Mays N (2006) Chapter 7 Analysing qualitative data. In: Pope C, Mays N, editors. Qualitative research in health care, 3rd ed. Oxford: Blackwell Publishing Ltd.
[29]
Hanson K, Palafox B, Anderson S, Guzman J, Moran M, et al.. (2011) Chapter 14 Pharmaceuticals. In: Merson MH, Black RE, Mills AJ, editors. Global Health: Diseases, Programs, Systems, and Policies, 3rd edition. Burlington, MA: Jones & Bartlett Learning.
[30]
Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, et al. (2009) Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. PLoS One 4: e6857. doi: 10.1371/journal.pone.0006857
[31]
Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, et al. (2011) The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial. PLoS Med 8: e1000437. doi: 10.1371/journal.pmed.1000437
[32]
Smith N, Obala A, Simiyu C, Menya D, Khwa-Otsyula B, et al. (2011) Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme. Malar J 10: 316. doi: 10.1186/1475-2875-10-316
[33]
Talisuna AO, Daumerie PG, Balyeku A, Egan T, Piot B, et al. (2012) Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study. Malar J 11: 356. doi: 10.1186/1475-2875-11-356
[34]
Kaplan W, Laing R (2005) Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines. An Overview of Key Concepts, Issues and Opportunities for Future Research. Washington, DC: The International Bank for Reconstruction and Development/The World Bank.
[35]
Taylor J, Bate R, Putze E, Tren R (2009) The push for local production, costs and benefits - A case study of Uganda’s Quality Chemicals. September 2009
[36]
Rutta E, Senauer K, Johnson K, Adeya G, Mbwasi R, et al. (2009) Creating a New Class of Pharmaceutical Services Provider for Underserved Areas: The Tanzania Accredited Drug Dispensing Outlet Experience. Progress in Community Health Partnerships: Research, Education, and Action 3 (Summer 2009): 145–153. doi: 10.1353/cpr.0.0063
[37]
Décret no 2000–450 du 11 Septembre 2000. Recueil des textes législatifs et réglementaires du secteur pharmaceutique. 2e édition. Decembre 2007.
[38]
Djankov S, Porta RL, Lopez-de-Silanes F, Shleifer A (2002) The Regulation of Entry. The Quarterly Journal of Economics 117: 1–37. doi: 10.1162/003355302753399436
